{
  "resourceType" : "Composition",
  "id" : "composition-diflucan",
  "meta" : {
    "versionId" : "1",
    "lastUpdated" : "2026-06-17T10:00:00Z",
    "profile" : ["http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/composition-epi-type1"]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"en\" xmlns=\"http://www.w3.org/1999/xhtml\" lang=\"en\"><p>Diflucan Summary of Product Characteristics</p></div>"
  },
  "identifier" : [{
    "system" : "http://example.org/identifier",
    "value" : "composition-diflucan"
  }],
  "version" : "1.0",
  "status" : "final",
  "type" : {
    "coding" : [{
      "system" : "https://spor.ema.europa.eu/rmswi",
      "code" : "100000155532",
      "display" : "Summary of Product Characteristics"
    }]
  },
  "subject" : [{
    "reference" : "http://hl7.org/fhir/uv/emedicinal-product-info/MedicinalProductDefinition/mpd-diflucan"
  }],
  "date" : "2026-06-17",
  "author" : [{
    "reference" : "Organization/org-diflucan"
  }],
  "title" : "Diflucan 150 mg capsule - Summary of Product Characteristics",
  "section" : [{
    "id" : "diflucan-root",
    "title" : "SUMMARY OF PRODUCT CHARACTERISTICS",
    "code" : {
      "coding" : [{
        "system" : "https://spor.ema.europa.eu/rmswi",
        "code" : "200000029791",
        "display" : "SUMMARY OF PRODUCT CHARACTERISTICS"
      }]
    },
    "text" : {
      "status" : "generated",
      "div" : "<div xml:lang=\"en\" xmlns=\"http://www.w3.org/1999/xhtml\" lang=\"en\">Summary of Product Characteristics for Diflucan</div>"
    },
    "section" : [{
      "id" : "diflucan-4-1",
      "title" : "4.1 Therapeutic indications",
      "code" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "200000029799",
          "display" : "4.1 Therapeutic indications"
        }]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xml:lang=\"en\" xmlns=\"http://www.w3.org/1999/xhtml\" lang=\"en\"><p>Treatment of mucosal and invasive candidiasis.</p></div>"
      },
      "entry" : [{
        "reference" : "ClinicalUseDefinition/cud-diflucan-mucosal"
      },
      {
        "reference" : "ClinicalUseDefinition/cud-diflucan-invasive"
      }]
    },
    {
      "id" : "diflucan-4-2",
      "title" : "4.2 Posology and method of administration",
      "code" : {
        "coding" : [{
          "system" : "https://spor.ema.europa.eu/rmswi",
          "code" : "200000029800",
          "display" : "4.2 Posology and method of administration"
        }]
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xml:lang=\"en\" xmlns=\"http://www.w3.org/1999/xhtml\" lang=\"en\"><p>Dose depends on the indication and the patient population (see structured dosing). Renal impairment requires dose adjustment for multiple-dose therapy.</p></div>"
      },
      "entry" : [{
        "reference" : "MedicationKnowledge/mk-diflucan"
      },
      {
        "reference" : "ClinicalUseDefinition/cud-diflucan-renal"
      }]
    }]
  }]
}